Gufic Biosciences Balance Sheet Health
Financial Health criteria checks 5/6
Gufic Biosciences has a total shareholder equity of ₹5.7B and total debt of ₹2.8B, which brings its debt-to-equity ratio to 49.4%. Its total assets and total liabilities are ₹11.0B and ₹5.3B respectively. Gufic Biosciences's EBIT is ₹1.3B making its interest coverage ratio 9. It has cash and short-term investments of ₹194.0M.
Key information
49.4%
Debt to equity ratio
₹2.84b
Debt
| Interest coverage ratio | 9x |
| Cash | ₹193.96m |
| Equity | ₹5.74b |
| Total liabilities | ₹5.30b |
| Total assets | ₹11.05b |
Recent financial health updates
Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?
Jun 17
These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well
Sep 02Gufic Biosciences (NSE:GUFICBIO) Has A Pretty Healthy Balance Sheet
Feb 11Gufic Biosciences (NSE:GUFICBIO) Has A Somewhat Strained Balance Sheet
Nov 13Recent updates
There's Reason For Concern Over Gufic Biosciences Limited's (NSE:GUFICBIO) Massive 26% Price Jump
Nov 07We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings
Jun 06Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?
Jun 17These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well
Sep 02Should You Be Adding Gufic Biosciences (NSE:GUFICBIO) To Your Watchlist Today?
May 07Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock
Dec 07This Is The Reason Why We Think Gufic Biosciences Limited's (NSE:GUFICBIO) CEO Might Be Underpaid
Sep 15Is Now The Time To Put Gufic Biosciences (NSE:GUFICBIO) On Your Watchlist?
Aug 12Gufic Biosciences' (NSE:GUFICBIO) Performance Is Even Better Than Its Earnings Suggest
Jun 11If You Like EPS Growth Then Check Out Gufic Biosciences (NSE:GUFICBIO) Before It's Too Late
Mar 19What Percentage Of Gufic Biosciences Limited (NSE:GUFICBIO) Shares Do Insiders Own?
Mar 01Gufic Biosciences (NSE:GUFICBIO) Has A Pretty Healthy Balance Sheet
Feb 11Is Gufic Biosciences' (NSE:GUFICBIO) 164% Share Price Increase Well Justified?
Jan 23
Why Gufic Biosciences Limited (NSE:GUFICBIO) Looks Like A Quality Company
Jan 05Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock
Dec 18Here's What Gufic Biosciences Limited's (NSE:GUFICBIO) Shareholder Ownership Structure Looks Like
Dec 01Gufic Biosciences (NSE:GUFICBIO) Has A Somewhat Strained Balance Sheet
Nov 13The Gufic Biosciences (NSE:GUFICBIO) Share Price Has Gained 116%, So Why Not Pay It Some Attention?
Oct 19Can Gufic Biosciences Limited's (NSE:GUFICBIO) ROE Continue To Surpass The Industry Average?
Sep 14I Built A List Of Growing Companies And Gufic Biosciences (NSE:GUFICBIO) Made The Cut
Aug 24Investors Appear Satisfied With Gufic Biosciences Limited's (NSE:GUFICBIO) Prospects
Aug 03Earnings Tell The Story For Gufic Biosciences Limited (NSE:GUFICBIO)
Jul 09Financial Position Analysis
Short Term Liabilities: GUFICBIO's short term assets (₹5.8B) exceed its short term liabilities (₹3.5B).
Long Term Liabilities: GUFICBIO's short term assets (₹5.8B) exceed its long term liabilities (₹1.8B).
Debt to Equity History and Analysis
Debt Level: GUFICBIO's net debt to equity ratio (46%) is considered high.
Reducing Debt: GUFICBIO's debt to equity ratio has reduced from 123.8% to 49.4% over the past 5 years.
Debt Coverage: GUFICBIO's debt is well covered by operating cash flow (24.6%).
Interest Coverage: GUFICBIO's interest payments on its debt are well covered by EBIT (9x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:52 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gufic Biosciences Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anil Burra | FirstCall Research |
| Naveed MD. | FirstCall Research |